---
layout: default
title: Aluminum Oxide Antimony Trisulfide Barium Carbonat
parent: 僅模型預測 (L5)
nav_order: 286
evidence_level: L5
indication_count: 0
---

# Aluminum Oxide Antimony Trisulfide Barium Carbonat
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Compound: Unable to Complete Repurposing Evaluation

---

## One-Sentence Summary

This submission contains a 20-component compound formula — including ingredients such as Epinephrine, Quinine Sulfate, Lithium Carbonate, and multiple botanical, mineral, and animal-derived substances — which is consistent in profile with a homeopathic or traditional combination preparation.
No TxGNN drug repurposing predictions were generated for this compound, and the product has **no regulatory approval record** in Taiwan.
Due to multiple critical data gaps and the absence of a unified drug identifier, a standard repurposing evaluation **cannot be completed** at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | Not available — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (no predictions, no supporting studies identified) |
| Market Status | Not marketed (Taiwan) |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why Evaluation Cannot Proceed

Currently, detailed mechanism of action data is not available. This product is a 20-ingredient compound formula spanning four material categories:

| Category | Ingredients |
|----------|-------------|
| **Chemical / Mineral** | Aluminum Oxide, Antimony Trisulfide, Barium Carbonate, Gold Monosulfide, Graphite, Lithium Carbonate, Selenium |
| **Botanical** | Conium maculatum (hemlock), Dioscorea villosa (wild yam), Guaiacum officinale, Lilium lancifolium, Solanum tuberosum, Toxicodendron vernix, Viola odorata |
| **Pharmaceutical** | Epinephrine, Quinine Sulfate |
| **Animal-derived** | Egg Phospholipids, Sepia officinalis juice (cuttlefish ink), Sus scrofa placenta (porcine placenta), Thyroid (bovine) |

TxGNN operates on individual drug entities mapped to DrugBank IDs through a knowledge graph. This multi-component mixture lacks a unified DrugBank identifier, making it incompatible with the standard single-entity prediction pipeline. Individual components such as Epinephrine (DB00668) and Quinine Sulfate (DB00468) do exist in DrugBank as separate entries, but the combination product as a whole has no recognized identity in the knowledge graph and cannot be scored.

The ingredient profile — particularly the use of highly diluted botanical toxins (Conium maculatum), mineral salts, and animal tissue extracts alongside conventional pharmaceuticals — is characteristic of classical homeopathic polypharmacy formulas (e.g., products registered under German homeopathic pharmacopoeia or HPUS standards). However, without a confirmed brand name, pharmacopoeial reference, or country-of-origin registration record, this interpretation cannot be confirmed.

---

## Safety Considerations

No structured safety data was retrieved for this compound as a whole. Individual components carry the following known safety signals that warrant attention:

- **Conium maculatum (poison hemlock)**: Highly toxic alkaloids (coniine, γ-coniceine); neuromuscular blockade risk even at low doses.
- **Quinine Sulfate**: Risk of cardiac arrhythmia (QT prolongation), cinchonism, and severe hypersensitivity reactions (thrombocytopenia, hemolysis).
- **Epinephrine**: Cardiovascular contraindications (hypertension, arrhythmia, coronary artery disease); interaction risk with MAOIs, tricyclic antidepressants, and beta-blockers.
- **Lithium Carbonate**: Narrow therapeutic index; renal and thyroid toxicity; significant drug-drug interactions.
- **Toxicodendron vernix (poison sumac)**: Contact dermatitis and systemic sensitization risk.
- **Barium Carbonate**: Systemic barium toxicity (hypokalemia, cardiac and skeletal muscle paralysis) at non-homeopathic doses.

A component-by-component safety review is **strongly recommended** before any clinical evaluation of this compound is considered.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This compound cannot be evaluated through the standard TxGNN drug repurposing pipeline. The absence of a unified DrugBank identifier, zero regulatory approval records, missing MOA data, and the multi-component nature of the formula collectively prevent scoring, evidence mapping, or safety profiling under the current framework.

**To proceed, the following is needed:**

- **Clarify product identity**: Obtain the official brand name, pharmacopoeial registration (e.g., HPUS, HAB, or equivalent), and country-of-origin regulatory filing. This is a blocking prerequisite.
- **Establish analytical strategy**: Decide whether to evaluate this product as a unified compound (requires finding a reference DrugBank/NDA entry) or decompose it into individual active components for parallel repurposing analysis.
- **Map individual components**: For a component-level analysis, map Epinephrine, Quinine Sulfate, Lithium Carbonate, and other pharmacologically active ingredients to their respective DrugBank IDs and run separate TxGNN queries.
- **Retrieve package insert / prescribing information**: Especially critical for Conium maculatum, Quinine Sulfate, and Epinephrine to address the Blocking data gap (DG001).
- **Obtain original indication(s)**: Without knowing what this product was originally intended to treat, the repurposing concept cannot be framed.
- **Confirm homeopathic classification**: If this is a registered homeopathic product, a separate evaluation framework for homeopathic repurposing may be more appropriate than the TxGNN pipeline designed for conventional pharmaceuticals.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

